Is it safe? What the controlled trials actually report

The question behind the question

Most people researching cell therapy start with “does it work?” But the question that actually keeps them up is quieter: could this make things worse? It is a fair question about any procedure, and it is a particularly fair one about a procedure you would travel for.

It also happens to be the question the published literature answers most clearly. Efficacy is still debated; the safety picture is comparatively consistent.

What 18 trials found

In June 2024, Tian and colleagues published a systematic review in Frontiers in Endocrinology pooling 18 randomized controlled trials with 1,174 participants. They looked specifically at treatment-related adverse events compared against placebo.

In plain terms: the confidence intervals cross 1.0, which means the analysis could not distinguish the rate of these side effects from the rate in patients who received a placebo. The authors state there was “no significant difference compared with the placebo group” for either.¹

Both reviews note transient fever as the most commonly mentioned systemic effect, which the authors attribute to the immunomodulatory activity of the cells rather than to anything going wrong.

What this does not mean

A clean safety signal in trials is genuinely good news. It is not the same as “risk-free,” and it would be dishonest to present it that way.

• Any joint injection carries risk. Infection, bleeding and a reaction to the procedure itself are possible with any needle entering a joint, regardless of what is in the syringe. This is one of several reasons the setting matters.
• Trials are not the real world. Participants are screened, protocols are controlled, and follow-up is systematic. Results from a well-run trial do not automatically transfer to a clinic with different standards.
• Follow-up has limits. These reviews cover short and medium term. Long-horizon safety data across decades does not yet exist for most of these preparations, and anyone who tells you otherwise is overstating.
• Preparations differ enormously. Cell source, processing, dose and handling vary between providers. A safety profile established for one protocol is not a guarantee for another. This is the single biggest reason to ask what, specifically, a clinic uses — and where it comes from.

Where the setting changes the arithmetic

Most of the residual risk in this picture is procedural rather than biological: it is about sterile technique, image guidance, correct handling of the biologic material, and what happens in the hours afterwards if something is not right.

That is a fairly ordinary list of things a surgical facility does every day and a consultation room does not. It is worth knowing which one you would be in — wherever you go.

Questions this evidence suggests you should ask

• What cell source and preparation do you use, and where is it sourced from?
• What documentation exists for that material — donor screening, certificate of analysis, cold-chain records?
• Is the procedure image-guided, and in what kind of facility is it performed?
• What is your protocol if there is a complication in the first 24 hours?
• What side effects should I expect, and for how long?
• What follow-up is scheduled, and with whom?

None of these are difficult questions for a clinic that has good answers.

See where procedures are performed at Medgenik →